---
title: 'A Multidimensional Approach to COPD'
---


The multifaceted nature of Chronic Obstructive Pulmonary Disease (COPD) defies simple explanations. Extensive research into its genetic and environmental underpinnings confirms that neither factor alone accounts for the disease’s prevalence and severity. As new genes associated with pulmonary function continue to be uncovered, a deeper understanding of the genetic mechanisms that drive COPD is anticipated.

The enduring impact of tobacco smoke stands out as a predominant risk factor, yet the role is complex. While tobacco smoke significantly exacerbates COPD, not all smokers develop the disease, suggesting that genetic predispositions and environmental exposures also play crucial roles. This complexity indicates COPD’s status as a multifactorial disease, where the interaction between genetics and environmental factors leads to the progressive decline in lung function characteristic of the disease.

Future research must focus on delineating how these factors contribute to COPD, potentially illuminating targeted strategies for prevention and treatment. By integrating genetic insights with environmental studies, the relative contributions of each factor to disease susceptibility and progression hope to be clarified.

As understanding of COPD's etiology advances, its pathogenesis will likely increasingly be seen as a product of intricate genetic and environmental interactions. This enhanced knowledge will not only improve diagnostic and therapeutic approaches but also offer hope for more personalized interventions, helping to alleviate the burden of this debilitating condition.


<details>
<summary>**References**</summary>

1.	Thoracickey. Pathogenesis of COPD: Persistence of Airway Inflammation – Why Does Airway Inflammation Persist After Cessation of Smoking? Available at: https://thoracickey.com/pathogenesis-of-copd-persistence-of-airway-inflammation-why-does-airway-inflammation-persist-after-cessation-of-smoking/. Accessed.
2.	Ghosh S, Pleasants RA, Ohar JA, Donohue JF, Drummond MB. Prevalence and factors associated with suboptimal peak inspiratory flow rates in COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:585-595. doi: 10.2147/COPD.S195438. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426426/
3.	Gedebjerg A, Szépligeti SK, Wackerhausen LH, et al. Prediction of mortality in patients with chronic obstructive pulmonary disease with the new Global Initiative for Chronic Obstructive Lung Disease 2017 classification: a cohort study. Lancet Respir Med. 2018;6(3):204-212. doi: 10.1016/S2213-2600(18)30002-X. Available from: https://www.bmj.com/content/378/bmj-2021-069679
4.	Bafadhel M, McKenna S, Terry S, et al. Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2011;184(6):662-671. doi: 10.1164/rccm.201104-0597OC. Available at: https://www.atsjournals.org/doi/full/10.1164/rccm.201104-0597OC
5.	Barnes P, Britton J, Hopkins J. Genetics and pulmonary medicine 9: Molecular genetics of chronic obstructive pulmonary disease. Thorax. 1999;54(3):245-252. Available at: http://thorax.bmj.com/content/54/3/245.info
6.	CDC. CDC - COPD Home Page - Chronic Obstructive Pulmonary Disease (COPD). Available at: https://www.cdc.gov/copd/index.html
7.	Christenson S, Steiling K. Shifting from Correlation to Causation: Challenges for the Future of Unbiased Molecular Studies in Inflammatory Lung Disease. Am J Respir Crit Care Med. 2017;195(1):5-7. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439941/
8.	Cosio Piqueras M, Cosio M. Disease of the airways in chronic obstructive pulmonary disease. Eur Respir J. 2001;18(1):41-49. Available at: http://erj.ersjournals.com/content/18/34_suppl/41s.long
9.	Eisner M, Anthonisen N, Coultas D, et al. An Official American Thoracic Society Public Policy Statement: Novel Risk Factors and the Global Burden of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2010;182(5):693-718. Available at: https://www.atsjournals.org/doi/full/10.1164/rccm.200811-1757ST
10.	European Lung Foundation - ELF. COPD. Available at: http://www.europeanlung.org/en/lung-disease-and-information/lung-diseases/copd
11.	Grigsby M, Siddharthan T, Chowdhury M, et al. Socioeconomic status and COPD among low- and middle-income countries. Int J Chron Obstruct Pulmon Dis. 2016;11:2497-2507. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065097/
12.	Halldin C, Doney B, Hnizdo E. Changes in prevalence of chronic obstructive pulmonary disease and asthma in the US population and associated risk factors. Chronic Respir Dis. 2015;12(1):47-60. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5588663/
13.	Hogg J. Lung structure and function in COPD. Int J Tuberc Lung Dis. 2008;12(5):467-479. Available at: http://www.ingentaconnect.com/content/iuatld/ijtld/2008/00000012/00000005/art00002;jsessionid=3kuh22qj6749c.x-ic-live-03
14.	Huertas A, Palange P. COPD: a multifactorial systemic disease. Ther Adv Respir Dis. 2011;5(3):217-224. Available at: http://journals.sagepub.com/doi/pdf/10.1177/1753465811400490
15.	Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. N Engl J Med. 2010;363(12):1128-1138. Available at: http://www.nejm.org/doi/full/10.1056/NEJMoa0909883
16.	Ingebrigtsen T, Thomsen SF, van der Sluis S, et al. Genetic Influences on Pulmonary Function: A Large Sample Twin Study. Lung. 2011;189(4):323-330. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3638153/
17.	Lomas DA, Silverman EK. The genetics of chronic obstructive pulmonary disease. Respir Res. 2001;2(1):20. Available at: https://respiratory-research.biomedcentral.com/articles/10.1186/rr34
18.	Nordestgaard BG, Dahl M. Markers of early disease and prognosis in COPD. Int J Chron Obstruct Pulmon Dis. 2009;4:157. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2672792/
19.	Powell R, Davidson D, Divers J, et al. Genetic ancestry and the relationship of cigarette smoking to lung function and per cent emphysema in four race/ethnic groups: a cross-sectional study. Thorax. 2013;68(7):634. Available at: http://thorax.bmj.com/content/68/7/634.info
20.	Qureshi H, Sharafkhaneh A, Hanania NA. Chronic obstructive pulmonary disease exacerbations: latest evidence and clinical implications. Ther Adv Chronic Dis. 2014;5(5):212-227. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4131503/
21.	Ray S, Guarascio A, Finch C, Self T. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res. 2013;5:235-245. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3694800/
22.	Seifart C, Plagens A. Genetics of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2007;2(4):541-550. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2699975/
23.	Sinden NJ, Stockley RA. Chronic obstructive pulmonary disease: an update of treatment related to frequently associated comorbidities. Ther Adv Chronic Dis. 2010;1(2):43-57. Available at: http://journals.sagepub.com/doi/pdf/10.1177/2040622310370631
24.	White AJ, Gompertz S, Stockley RA. Chronic obstructive pulmonary disease 6: The aetiology of exacerbations of chronic obstructive pulmonary disease. Thorax. 2003;58(1):73-80. Available at: http://thorax.bmj.com/content/58/1/73.info

</details>